ASCO 2019 | Tailored treatment strategies for CLL

Danielle Brander

Here, Danielle Brander, MD, of the Duke University School of Medicine, Durham, NC, discusses tailored treatment strategies for chronic lymphocytic leukemia (CLL), including the use of B-cell receptor signalling inhibitors, and the BCL-2 inhibitor venetoclax. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics